BPC-157, TB-500, and GHK-Cu for sciatica: what the evidence says

What did @jddenhamfit actually say?

The creator described a daily injection protocol of three peptides, taken two to three times per day, to address sciatic nerve pain. Specifically: "20 units of TB-500, which would be about 2 milligrams," the same dose of BPC-157, and "20 units of GHK-Cu, which would be about 5 milligrams." They inject this mixture directly into the gluteal area near the sciatic nerve and report pain dropping from a 9 out of 10 to roughly a 1 or 2. They add the standard disclaimer: "I'm not a doctor, I'm not telling you should." That's the claim on the table. Three unregulated peptides, injected locally, multiple times daily, with near-complete pain relief attributed to the protocol.

Does the science back this up?

For BPC-157, there is genuine preclinical signal. The evidence for TB-500 in humans is essentially nonexistent. GHK-Cu data in this context is thin. Calling this "backed by science" would be a stretch. Preclinical work is not clinical proof.

BPC-157 has the strongest animal-model evidence of the three. Studies in rodents show anti-inflammatory and nerve-protective effects. Hsieh et al. (2017, Journal of Orthopaedic Surgery and Research) demonstrated BPC-157 accelerated peripheral nerve healing in rats. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed multiple mechanisms including nitric oxide modulation. No peer-reviewed human RCT exists for sciatica specifically.

TB-500 (a synthetic fragment of Thymosin Beta-4) has animal data for wound healing and cardiac repair, but zero published human trials for musculoskeletal or nerve pain. GHK-Cu has tissue-repair and anti-inflammatory properties documented in cell studies (Pickart et al., 2015, Journal of Aging Research), but again, no human trial supports the specific use described here.

What did they get wrong (or right)?

Credit where it's due: the creator did not claim this would work for anyone else, and they disclosed they are not a doctor. That restraint matters. But several things are wrong or missing.

First, the dosing math is off. For GHK-Cu, 20 units on a standard 100-unit insulin syringe from a 10mg/mL vial equals 2mg, not 5mg. If the vial concentration is 25mg/mL, the math changes. The creator does not specify vial concentration, which makes their dosing information not just imprecise but potentially dangerous to anyone trying to replicate it. Peptide vials vary widely in concentration and anyone copying this without knowing their vial specs could dramatically over- or underdose.

Second, the claim of "95%" pain reduction is anecdote, not evidence. Sciatica fluctuates naturally. Regression to the mean, placebo response, concurrent lifestyle changes, or the simple passage of time could explain most of the improvement. Attributing it entirely to this three-peptide stack is a logical leap the data does not support.

Third, injecting directly into the gluteal region near the sciatic nerve without medical supervision carries real risk, including nerve injury, abscess, and injection-site infection.

What should you actually know?

These peptides are not FDA-approved for any therapeutic use. They are research compounds. Buying them, injecting them, and adjusting doses based on a TikTok video is a significant medical risk, regardless of what the creator personally experienced.

BPC-157 is the most studied of the three and has a plausible biological rationale for nerve and connective tissue repair. But "plausible rationale" and "proven treatment" are not the same category. TB-500 has a loyal following in fitness and biohacker communities, but community enthusiasm does not replace clinical trial data. GHK-Cu in injectable form for pain is largely uncharted territory in human research.

If you have sciatic nerve pain at a 9 out of 10, the responsible path includes imaging, a qualified provider, and evidence-based options like physical therapy, NSAIDs, or epidural steroid injections, all of which have actual clinical trial support. Peptide therapy may one day have a legitimate role in nerve recovery. Right now, for sciatica, it is experimental at best.

• None of these three peptides are approved for human therapeutic use by the FDA.
• Vial concentration was never stated, making dose replication unreliable and potentially unsafe.
• The sciatic nerve runs through the gluteal region, and self-injection near it without imaging guidance is not a minor risk.
• Anyone considering peptides should work with a licensed provider who can supervise sourcing, dosing, and monitoring.